Hope vs hype: Doctors split over ‘game-changing’ experimental Alzheimer’s drug
Some experts say the benefits of lecanemab are “extremely small”, but others including Associate Professor Michael Woodward dispute this
“Impressive”. “Remarkable”. “Game-changing”.
There was no shortage of praise for the experimental dementia drug lecanemab following the release of phase III trial results late last year.
The study, involving 1800 patients with early Alzheimer’s disease, represents perhaps the most significant scientific advance in the field for decades.
And, as many experts have pointed out, it appears to confirm the so-called ‘amyloid hypothesis’ that implicates the accumulation of beta-amyloid in the pathogenesis of this neurodegenerative condition.
